Novo Nordisk, Hims End Ozempic-Wegovy Suit With Distribution Deal
Hims will sell branded Ozempic and Wegovy and stop advertising compounded GLP-1s as Novo drops its patent suit while reserving the right to refile.
GizmodoNovo Nordisk and Hims End Their Ozempic War. Hereâs What It Means for You
USA TODAYNovo Nordisk deal lets Hims sell Wegovy and Ozempic, drops lawsuit
ABC NewsHims & Hers Health, Novo Nordisk end weight loss medication suit, enter collaboration
CNBCHims & Hers shares surge after Novo Nordisk drops patent infringement case over compounded weight loss drugs
Washington ExaminerHims & Hers stock price soars following weight loss drug deal
Overview
On Monday Novo Nordisk said it will sell Wegovy and Ozempic through Hims & Hers' platform and withdrew its patent infringement lawsuit while reserving the right to refile.
Novo sued Hims in February over compounded versions of Wegovy and GLP-1 injectables after Hims briefly launched a compounded Wegovy pill and the FDA warned against mass-marketing copycat drugs.
FDA Commissioner Marty Makary said he welcomed Hims stopping advertising unapproved compounded drugs and cited that compounded GLP-1s will be limited to rare FDA-compliant cases, according to his post on X.
Novo said the Wegovy pill generated more than 600,000 prescriptions since its launch two months ago, and the FDA last week warned 30 telehealth companies about misleading promotions of compounded GLP-1s.
Under the deal Hims will offer injectable and oral versions of Wegovy and Ozempic at Novo's self-pay prices, Hims will stop advertising compounded GLP-1s, and Novo reserved the right to refile its lawsuit.
Analysis
Center-leaning sources frame the deal as a decisive truce that benefits consumers by using conflict metaphors (war, ceasefire, scuffle) and evaluative terms (backed down, brazenly selling, shady). They prioritize corporate and FDA voices while giving limited space to patient advocates or compounding pharmacists, emphasizing market resolution over policy nuance.
FAQ
Compounded GLP-1 drugs are customized versions of weight-loss medications created by pharmacies to match individual patient needs, often marketed at lower prices than branded alternatives[2]. Hims & Hers initially offered compounded versions of semaglutide (the active ingredient in Novo's drugs) while FDA-approved supplies were scarce[2]. Unlike FDA-approved Ozempic and Wegovy, which undergo rigorous safety and efficacy testing, compounded drugs are individually mixed and have not undergone the same regulatory evaluation[3]. Under the new deal, Hims will only offer compounded versions when a clinician determines it is clinically necessary rather than advertising them as primary alternatives.
Novo sued Hims in February 2026 for patent infringement after Hims launched a $49 compounded copy of Novo's obesity pill and continued marketing compounded GLP-1 drugs despite regulatory scrutiny[1][3]. The FDA also warned against mass-marketing of copycat drugs, and Novo's general counsel called Hims' move "egregious"[4]. The settlement was motivated by commercial considerations: Novo faced significant headwinds from telehealth firms offering cheaper compounded versions, while Hims faced the prospect of a costly legal battle[1]. The deal allows both companies to benefit—Novo gains access to Hims' large direct-to-consumer platform to compete with Eli Lilly, while Hims can offset potential compounded GLP-1 revenue declines by selling branded products[2].
While the deal is positive for Hims' stock price—shares surged over 40% on the announcement[1]—the financial impact remains uncertain. Selling Novo's branded products will generate higher revenue contribution but likely produce lower profit margins compared to Hims' compounded offerings[1]. However, Hims' CEO Andrew Dudum framed the shift as strategic, citing "tremendous growth opportunities" as branded GLP-1 medicines become more affordable and accessible[3]. Analysts expect the deal to offset potential declines in compounded GLP-1 sales rather than provide immediate margin expansion[2].
By reserving the right to refile, Novo maintains legal leverage if Hims violates the agreement terms, particularly regarding its commitment to stop advertising compounded GLP-1 drugs[3]. This clause protects Novo's intellectual property while allowing the current partnership to proceed without full legal settlement[3]. However, the agreement demonstrates both companies' preference for collaboration over protracted litigation, especially given the rapid growth projections for the GLP-1 market, which is expected to reach approximately 25 million Americans by 2030[4].
Novo reported that the Wegovy pill generated more than 600,000 prescriptions since its launch two months ago, demonstrating strong market demand[3]. This performance reflects broader expansion in the GLP-1 market driven by new oral formulations, increased insurance coverage, and growing global supply[4]. J.P. Morgan projects the weight-loss drug market will become one of the largest and fastest-growing segments in healthcare, with demand skyrocketing as access improves[4]. The Novo-Hims partnership capitalizes on this momentum by making both injectable and oral versions available through a major telehealth platform[1].
